Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32472948.
- Also identified by DOI 10.1002/cncr.32983 and PMC identifier 7300674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This commentary proposes a shift in the current diagnostic workflow for patients with metastatic cancer to incorporate the use of liquid biopsy. This proposal, born in the time of a severe crisis for the health care system, might also be applied when the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) outbreak ends and thereby reduce the turnaround time for results from molecular testing for patients with cancer and increase the number of patients potentially benefiting from highly effective targeted therapies.
Medical subject headings
- COVID-19
- Liquid Biopsy
- Neoplasms